Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 39Unknown 11Terminated 11Recruiting 5Active not recruiting 3Withdrawn 2Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 5Nivolumab 3Biopsy 3Magnetic Resonance Spectroscopy 2Docetaxel 2talazoparib 1romidepsin 1pembrolizumab 1olaparib 1imisopasem manganese 1gallium 68 PSMA-11 1durvalumab 1cabozantinib 1balstilimab 1aldesleukin 1abivertinib 1abiraterone 1abarelix 1Watchful Waiting 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Pluvicto 1Palliative Care 1Paclitaxel 1Observation 1N-acetylcochinol-O-phosphate 1Mental Status and Dementia Tests 1Menogaril 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × aldesleukin × Genitourinary × Clear all
NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡